{"id":"x842","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, X842 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"X842 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:03.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07107672","phase":"PHASE1","title":"Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2022-06-15","conditions":"Gastroesophageal Reflux Disease","enrollment":6},{"nctId":"NCT07079540","phase":"PHASE3","title":"The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2021-06-24","conditions":"Reflux Esophagitis","enrollment":380},{"nctId":"NCT04531475","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2020-01-21","conditions":"Reflux Esophagitis","enrollment":90},{"nctId":"NCT05627518","phase":"PHASE1","title":"Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation","status":"COMPLETED","sponsor":"Cinclus Pharma Holding AB","startDate":"2022-11-15","conditions":"Safety, Bioavailability, Pharmacokinetics","enrollment":67},{"nctId":"NCT05469854","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate","status":"UNKNOWN","sponsor":"Cinclus Pharma AG","startDate":"2022-07-13","conditions":"Pharmacokinetics, Cardiodynamic ECG, Safety, and Tolerability","enrollment":113},{"nctId":"NCT05055128","phase":"PHASE2","title":"A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole","status":"COMPLETED","sponsor":"Cinclus Pharma AG","startDate":"2021-08-11","conditions":"Erosive Esophagitis","enrollment":248},{"nctId":"NCT04293965","phase":"PHASE1","title":"Single-dose and Multiple-dose X842 Phase 1 Study","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2018-10-23","conditions":"Healthy Volunteers","enrollment":80},{"nctId":"NCT03105375","phase":"EARLY_PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study","status":"COMPLETED","sponsor":"Cinclus Pharma AG","startDate":"2017-02-21","conditions":"Healthy Volunteers","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Undecided","X842 capsules"],"phase":"phase_3","status":"active","brandName":"X842","genericName":"X842","companyName":"Jiangsu Sinorda Biomedicine Co., Ltd","companyId":"jiangsu-sinorda-biomedicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"X842 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}